Guideline for the Management of Fever and Neutropenia in Children With Cancer and/or Undergoing Hematopoietic Stem-Cell Transplantation

Thomas Lehrnbecher(Goethe University Frankfurt), Robert Phillips(Goethe University Frankfurt), Sarah Alexander(Goethe University Frankfurt), Frank Alvaro(Goethe University Frankfurt), Fabianne Carlesse(Goethe University Frankfurt), Brian T. Fisher(Goethe University Frankfurt), Hana Hakim(Goethe University Frankfurt), Marı́a Elena Santolaya(Goethe University Frankfurt), Elio Castagnola(Goethe University Frankfurt), Bonnie L. Davis(Goethe University Frankfurt), L. Lee Dupuis(Goethe University Frankfurt), Faith Gibson(Goethe University Frankfurt), Andreas H. Groll(Goethe University Frankfurt), Aditya H. Gaur(Goethe University Frankfurt), Ajay Gupta(Goethe University Frankfurt), Rejin Kebudi(Goethe University Frankfurt), Sérgio Petrilli(Goethe University Frankfurt), William J. Steinbach(Goethe University Frankfurt), Milena Villarroel(Goethe University Frankfurt), Theoklis E. Zaoutis(Goethe University Frankfurt), Lillian Sung(Goethe University Frankfurt)
Journal of Clinical Oncology
September 18, 2012
Cited by 351Open Access
Full Text

Abstract

PURPOSE: To develop an evidence-based guideline for the empiric management of pediatric fever and neutropenia (FN). METHODS: The International Pediatric Fever and Neutropenia Guideline Panel is a multidisciplinary and multinational group composed of experts in pediatric oncology and infectious disease as well as a patient advocate. The Panel was convened for the purpose of creating this guideline. We followed previously validated procedures for creating evidence-based guidelines. Working groups focused on initial presentation, ongoing management, and empiric antifungal therapy. Each working group developed key clinical questions, conducted systematic reviews of the published literature, and compiled evidence summaries. The Grades of Recommendation Assessment, Development, and Evaluation approach was used to generate summaries, and evidence was classified as high, moderate, low, or very low based on methodologic considerations. RESULTS: Recommendations were made related to initial presentation (risk stratification, initial evaluation, and treatment), ongoing management (modification and cessation of empiric antibiotics), and empiric antifungal treatment (risk stratification, evaluation, and treatment) of pediatric FN. For each recommendation, the strength of the recommendation and level of evidence are presented. CONCLUSION: This guideline represents an evidence-based approach to FN specific to children with cancer. Although some recommendations are similar to adult-based guidelines, there are key distinctions in multiple areas. Implementation will require adaptation to the local context.


Related Papers

No related papers found

Powered by citation graph analysis